- 24 Tech Roqad st Ny 10023
- editech@mail.com
Mr. Vivek Sharma was appointed Executive Chairman of Suven Pharmaceuticals effective September 20, 2024. He is responsible for steering the company’s overall business operations, driving strategic growth initiatives, and enhancing shareholder value. With more than 25 years of global experience spanning the life sciences and financial sectors, Mr. Sharma brings a distinctive combination of expertise in pharmaceutical services, data analytics, and artificial intelligence (AI).
His deep understanding of the CDMO (Contract Development and Manufacturing Organization) sector is underpinned by a strong track record in leadership roles across prominent organizations. Notably, he served as CEO of Piramal Pharma Solutions (2014–2019), where he led global growth and operational excellence. He later held leadership roles as Chairman & CEO at Adare Pharma Solutions (2020–2022), CEO of Decision Resources Group (2019–2020), and most recently as CEO of Saama Technologies, an AI-driven clinical analytics firm (2022–2024). In recognition of his industry contributions, Mr. Sharma was honoured as Global CEO of the Year by the CPhI Pharma Awards in 2015.
He holds an Executive MBA from the Thunderbird School of Global Management and is a Chartered and Certified Public Accountant (CPA). Outside of his corporate pursuits, Mr. Sharma is an active philanthropist, supporting initiatives in women’s empowerment, education, and environmental sustainability. He has served on the board of CEM since 2019 and continues to hold directorships across various biotech and technology start-ups.
Other Directorships / Full-time Positions in Body Corporates:
SI | Name of the Company / Body Corporate | Position |
1 | Apollo Intelligence Operation LLC | Director |
2 | Aigilx Health | Director |
3 | Brooks School, Andover, MA | Trustee, Board of Trustees |
4 | NJ Bio Inc. | Director |
Read More
Mr. Vivek Sharma was appointed Executive Chairman of Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) effective September 20, 2024. He is responsible for steering the company’s overall business operations, driving strategic growth initiatives, and enhancing shareholder value. With more than 25 years of global experience spanning the life sciences and financial sectors, Mr. Sharma brings a distinctive combination of expertise in pharmaceutical services, data analytics, and artificial intelligence (AI).
His deep understanding of the CDMO (Contract Development and Manufacturing Organization) sector is underpinned by a strong track record in leadership roles across prominent organizations. Notably, he served as CEO of Piramal Pharma Solutions (2014–2019), where he led global growth and operational excellence. He later held leadership roles as Chairman & CEO at Adare Pharma Solutions (2020–2022), CEO of Decision Resources Group (2019–2020), and most recently as CEO of Saama Technologies, an AI-driven clinical analytics firm (2022–2024). In recognition of his industry contributions, Mr. Sharma was honoured as Global CEO of the Year by the CPhI Pharma Awards in 2015.
He holds an Executive MBA from the Thunderbird School of Global Management and is a Chartered and Certified Public Accountant (CPA). Outside of his corporate pursuits, Mr. Sharma is an active philanthropist, supporting initiatives in women’s empowerment, education, and environmental sustainability. He has served on the board of CEM since 2019 and continues to hold directorships across various biotech and technology start-ups.
Other Directorships / Full-time Positions in Body Corporate Entities:
SI | Name of the Company / Body Corporate | Position |
1 | Apollo Intelligence Operation LLC | Director |
2 | Aigilx Health | Director |
3 | Brooks School, Andover, MA | Trustee, Board of Trustees |
4 | NJ Bio Inc. | Director |
Executive Chairman
Mr. Vivek Sharma was appointed Executive Chairman of Suven Pharmaceuticals effective September 20, 2024.
Executive Chairman
Dr. V. Prasada Raju was appointed Managing Director of Suven Pharmaceuticals on September 29, 2023.
Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
SI | Name of the Company / Body Corporate | Position |
1 | Apollo Intelligence Operation LLC | Director |
2 | Aigilx Health | Director |
3 | Brooks School, Andover, MA | Trustee, Board of Trustees |
4 | NJ Bio Inc. | Director |
Dr. V. Prasada Raju was appointed Managing Director of Suven Pharmaceuticals on September 29, 2023. He also serves as the CEO and Managing Director of Cohance Lifesciences Ltd.Dr. Raju brings over three decades of comprehensive experience in the pharmaceutical industry, with strong credentials in strategy, operations, scientific affairs, and business development. Previously, he was Executive Director at Granules India Ltd, where he played a pivotal role in shaping growth strategy, managing the product pipeline, leading regulatory and intellectual property functions, and spearheading new business initiatives. He was also instrumental in setting up R&D and Greenfield manufacturing projects.
In his earlier roles, Dr. Raju served on the boards of several key entities, including Granules Omnichem Pvt. Ltd. (Vizag, India), Granules Pharmaceuticals Inc. (Washington, D.C., USA), and USpharma Ltd. (Florida, USA). He spent nearly two decades at Dr. Reddy’s Laboratories (1994–2012), holding senior positions with responsibilities spanning technical, strategic, and operational leadership.
Dr. Raju holds a PhD in Chemistry and a Postgraduate Diploma in Patent Law, and has undergone specialized training in material sciences at IIT, Chicago, USA. He is also an alumnus of the Senior Management Program at the Indian Institute of Management, Calcutta (IIMC).
Dr. Raju’s diverse expertise and leadership acumen position him as a highly respected figure in the pharmaceutical sector.
Other Directorships / Full-time Positions in Body Corporates:
SI | Name of the Company / Body Corporate | Position |
1 | Cohance Lifesciences Limited | Managing Director |
2 | Sapala Organics Private Limited | Director |
Mr. Pankaj Patwari was appointed as a Non-Executive Director of the Company effective 29th September 2023. A Chartered Accountant by training, he also holds an MBA from the Indian Institute of Management, Lucknow.
Mr. Patwari is Managing Director at Advent India PE Advisors Private Limited, where he has led investments in Manjushree Technopack Limited and Bharat Serums and Vaccines Limited. His previous board affiliations include Manjushree Technopack and Gokaldas Intimatewear. Earlier, he worked with Bain Capital for six years, focusing on pharmaceutical and industrial transactions, and spent four years at McKinsey & Company with a concentration on financial services.
Other Directorships / Positions in Body Corporates:
SI | Name of the Company / Body Corporate | Position |
1 | Apollo Healthco Limited | Director |
2 | Keimed Private Limited | Director |
3 | Advent India PE Advisors Private Limited | Director |
4 | Cohance Lifesciences Limited | Non-Executive Chairman |
Mr. K G Ananthakrishnan joined as an Independent Director of the Company effective 29th September 2023. He has had a distinguished career spanning over four decades in the pharmaceutical industry.
He served as Director General of the Organization of Pharmaceutical Producers of India (OPPI) and Co-Chair of the Pharma Committee at CII, where he played a key role in shaping public policy. He holds a Masters in Marketing Management from JBIMS, Mumbai, and a Bachelors in Science from Osmania University, Hyderabad. He has also completed executive programs at Wharton Business School and INSEAD. Beginning his career with Novartis India in 1976, he held senior roles at Pharmacia, Pfizer, and Fulford (India). As VP and MD – South Asia Region for MSD, he led a transformation into a high-growth company.
Other Directorships / Positions in Body Corporates:
SI | Name of the Company / Body Corporate | Position |
1 | Gujarat Themis Biosyn Ltd | Independent Director |
2 | Rubicon Research Limited | Independent Director |
3 | Sapala Organics Private Limited | Independent Director |
4 | Punjab National Bank | Non-Executive Chairman |
5 | Mango Cancer Care Foundation | Non-Executive Director |
Ms. Matangi Gowrishankar was appointed as an Independent Director of the Company effective 29th September 2023. A Strategic Advisor and Certified Coach, she has 40+ years of global leadership experience.
Previously, she was the Global Head of Capability Development at BP, where she drove leadership and talent transformation. Ms. Gowrishankar has collaborated closely with senior leaders across industries, offering expertise in contemporary leadership, digital transformation, and culture-building for sustainable growth.
Other Directorships / Positions in Body Corporates:
SI | Name of the Company / Body Corporate | Position |
1 | Greenlam Industries Limited | Independent Director |
2 | Cyient Limited | Independent Director |
3 | Akums Drugs and Pharmaceuticals Limited | Independent Director |
4 | Gujarat Pipavav Port Limited | Independent Director |
5 | IDFC First Bank Limited | Independent Director |
6 | Premium Transmission Limited | Director |
7 | Premium Motion Private Limited | Director |
8 | Intellecap Advisory Services Private Limited | Director |
9 | Anudip Foundation for Social Welfare | Director |
10 | Cyient Europe Limited | Director |
Mr. Vinod Rao was appointed as an Independent Director effective 29th September 2023. He is also a Director at Eureka Forbes. With over 35 years of experience, Mr. Rao has held senior roles at Diageo, PepsiCo, and ICI across consumer goods, industrial products, and consumer durables.
His leadership spans global markets including India, Southeast Asia, China, the UK, and Europe, giving him wide-ranging business and operational exposure.
Other Directorships / Positions in Body Corporates:
SI | Name of the Company / Body Corporate | Position |
1 | Eureka Forbes Limited | Independent Director |
2 | Cohance Lifesciences Limited | Independent Director |
3 | Isha Foundation, UK | Designated Partner |
Mr. Pravin Rao joined the Company as an Independent Director on 9th November 2023. A graduate in Electrical Engineering from Bangalore University, Mr. Rao has over 35 years of experience in the technology sector.
He began his career at Infosys in 1986 and rose to become Chief Operating Officer and Board Member before his retirement in December 2022. He currently serves as an Independent Director on the boards of several leading firms in financial services and health-tech.
Other Directorships / Positions in Body Corporates:
SI | Name of the Company / Body Corporate | Position |
1 | Sowparnika Retail Private Limited | Independent Director |
2 | Computer Age Management Services Limited | Independent Director |
3 | Zensar Technologies Limited | Independent Director |
4 | Indegene Limited | Independent Director |
5 | Axis Finance Limited | Independent Director |
Ms. Shweta Jalan joined as a Non-Executive Director of the Company on 9th November 2023. She has been Managing Director at Advent India PE Advisors since 2009.
She has prior experience at ICICI Venture and Ernst & Young. Ms. Jalan has led transactions across industrials, media, IT/BPO, and business services. She advises on investment structuring, growth strategies, and successful exits.
Other Directorships / Positions in Body Corporates:
SI | Name of the Company / Body Corporate | Position |
1 | Sowparnika Retail Private Limited | Director |
2 | Yes Bank Limited | Non-Executive – Non-Independent Director |
3 | Modenik Lifestyle Private Limited | Director |
4 | Cohance Lifesciences Limited | Non-Executive – Non-Independent Director |
5 | Manjushree Technopack Limited | Director |
Mr. Vinod Padikkal is a Senior Portfolio Manager at the Abu Dhabi Investment Authority (ADIA), overseeing private equity investments in India and Southeast Asia. He joined ADIA in 2021.
He previously held roles at Advent International, Bain Capital, and Bain & Company, where he focused on investment strategy and operational improvement. He holds a B.Tech in Computer Science from Cochin University and an MBA from IIM Ahmedabad.
Other Directorships / Positions in Body Corporates:
SI | Name of the Company / Body Corporate | Position |
1 | Nil | Nil |
Mr. Jai Shankar Krishnan has been driving growth for Danaher Corporation in High Growth Markets since 2019. He began his tenure at Danaher in 2008 as President and CEO – India, and later expanded his leadership to Southeast Asia and other global regions.
Prior to Danaher, he held senior positions at PerkinElmer, Novartis, GSK, and began his career at Hindustan Unilever. Mr. Krishnan holds an MBA from BIT, is a Harvard Business School alumnus, and is a certified coach and Lean Six Sigma Master Black Belt.
Other Directorships / Positions in Body Corporates:
SI | Name of the Company / Body Corporate | Position |
1 | Wellness Forever Medicare Limited | Director |
2 | Lineology Private Limited | Director |
3 | Arkanova LLP | Trustee, Board of Trustees |
The Executive Leadership Team drives operational excellence and strategic execution across Cohance’s global operations. With deep experience in life sciences, CDMO growth, and regulatory compliance, they lead with agility and purpose.
Appointed: 29 September 2023
Dr. Sudhir Kumar Singh is the Chief Executive Officer of the Company. A distinguished scientist and industry leader, he holds a PhD in Medicinal Chemistry from the Central Drug Research Institute, one of India’s premier research institutions. He completed his postdoctoral fellowship in the USA and served as a faculty member at Rutgers University, New Jersey.
With over three decades of experience in the pharmaceutical and biotech industry, Dr. Singh has held leadership roles including Chief Operating Officer at Aragen Life Sciences Ltd., where he led India’s largest Contract Development and Manufacturing Organization (CDMO) with a team of over 2,000 scientists. His strategic vision and deep expertise in drug discovery and development have consistently driven organizational growth and innovation.
A pioneer in his field, Dr. Singh has contributed significantly to the advancement of novel therapies through research excellence and patented innovations.
Appointed: 29 September 2023
Mr. Gaurav Bahadur is the Chief Human Resources Officer of the Company, responsible for leading the people strategy and HR functions.
He brings a strong track record in shaping performance-driven cultures across leading organizations such as Vodafone Essar, Yahoo! India, Philips India, and Sanofi India—where he led key HR transformations. Gaurav holds a Masters degree in Personnel Management from the Symbiosis Institute of Business Management and a Bachelors degree in Chemistry from St. Xavier’s College, Mumbai.
His expertise in driving strategic human capital initiatives plays a key role in aligning talent development with the company’s business goals.
Appointed: 2 January 2024
Mr. Himanshu Agarwal is the Chief Financial Officer of the Company and oversees Finance, IT, Legal, Secretarial, and Investor Relations.
He brings 29 years of professional experience, having held senior roles at ICI India, AstraZeneca Pharma, Akzo Nobel India, Huhtamaki Oyj, and Bennett, Coleman & Co. Ltd. Himanshu’s deep expertise spans finance, M&A, investor relations, business strategy, and technology enablement across sectors including pharmaceuticals, packaging, media, chemicals, and coatings.
A rank-holder Chartered Accountant, Company Secretary, and Cost and Management Accountant, Himanshu has led numerous strategic initiatives including finance transformation, profit turnaround, value chain optimization, and M&A integrations. He has also enabled enterprise-wide technology adoption—from ERP systems to BOTs—and was awarded ‘Best CFO’ by the Institute of Chartered Accountants of India.
Dr. K. Nagendra Babu brings over 25 years of rich experience across Finished Dosage Forms and APIs in the areas of Global Audit and Compliance, Vendor and Third-Party Management, QA, QC, DQA, CQA, and manufacturing.
He has held leadership roles in top pharma companies including Mylan (Viatris), Gravity Pharmaceuticals, Granules India, GSK Pharmaceuticals, Dr. Reddy’s Laboratories, and Aurobindo Pharma. Dr. Babu holds a PhD in Chemistry and has undergone extensive training in regulatory compliance and GxP audits.
He works closely with Quality Operations, Regulatory Affairs, and the broader Operations team to implement industry-leading quality and compliance systems and standards.
Our Advisory Board provides specialized insights into emerging therapeutic modalities, regulatory trends, and global market dynamics. Their guidance strengthens our ability to deliver cutting-edge solutions to our partners.
Mr. Annaswamy Vaidheesh is a seasoned business leader with over 35 years of experience across some of the most admired Fortune 100 companies in the healthcare and FMCG sectors, including Johnson & Johnson, Pfizer, and GSK. He brings deep expertise in general management, market creation, and leadership development across multi-cultural and multi-market environments in the Asia-Pacific region.
He has served as President of the Organization of Pharmaceutical Producers of India (OPPI) and chaired several committees of leading industry bodies. Recognized by organizations such as The Economic Times for his leadership excellence, he has also served as an Operating Partner with Advent International.
Mr. Venkateswarlu Jasti holds postgraduate degrees in Pharmacy from Andhra University, Visakhapatnam, and St. John’s University, New York, specializing in Industrial Pharmacy.
A pioneer of the CRAMS business model in India, Mr. Jasti founded Suven Pharma Ltd. and Suven Life Sciences Ltd., leading their growth since inception in 1989. Under his leadership, Suven Life Sciences developed a robust discovery pipeline, including SUVN-502 (Phase 3 trials in the US for Alzheimer’s-related agitation) and SUVN-G3031 (Phase 2 completed for narcolepsy).
He has played instrumental roles in forming the AP Chief Minister’s Task Force for Pharma, establishing Pharma City in Visakhapatnam, and launching PHARMEXCIL. He has held leadership positions in industry associations such as the Indian Pharmaceutical Association and the Bulk Drug Manufacturers Association of India.
Appointed: October 2023
Mr. Stefan Stoffel is an accomplished operations leader with over 35 years of experience in production engineering, plant operations, and supply chain management. He holds an engineering degree from Lucerne University of Applied Sciences and Arts, Switzerland.
Formerly the COO of Lonza, Mr. Stoffel has held key positions including Head of Lonza Pharma & Biotech Strategic Growth Investments and Ibex Solutions, and General Manager of Lonza’s Chemical Operations Business Unit. He brings unmatched experience in managing complex global operations and driving strategic growth across the life sciences sector.
Appointed: October 2023
Mr. Abhijit Mukherjee is a chemical engineer from IIT Kharagpur and brings decades of operational and leadership experience in the pharmaceutical and chemical industries.
He served Dr. Reddy’s Laboratories for over 15 years, most recently as Chief Operating Officer from 2014 until his retirement in 2018. His earlier stints include leadership roles at Hindustan Unilever (13 years) and Atul Ltd. (9 years). He currently serves on the boards of Bharat Serums and Vaccines Ltd., ZCL Chemicals Ltd., and ICE, Milan (Italy).
.
Mr. Will Downie is a globally respected biopharma services executive and two-time CDMO CEO with a proven track record in commercial transformation and value creation.
As CEO of Vectura, he repositioned the company as a leader in inhalation CDMO, doubling its value and leading its strategic sale. At Argenta, he built the world’s top CRO/CDMO in animal health under KKR ownership. As CCO of Catalent, he helped drive its evolution into a top-three global CDMO and supported its transition to a NYSE-listed company.
Currently a Strategic Advisor to Boards and an Operating Partner with a leading private equity firm, he focuses on commercial strategy, transformation, and leadership in the pharma and CDMO industries.
Mr. Mark Peacock is a seasoned global operations leader with 30 years of experience across the AgChem, specialty chemicals, and pharmaceutical industries.
He spent over a decade as a member of the Executive Team at Syngenta, where he led global operations across supply, manufacturing, technology, HR, IS, and marketing. Known for driving business transformation and productivity, he brings deep expertise in systems thinking, change management, and operational excellence.
Mr. Bhasker Iyer is a strategic business leader with over four decades of experience in pharmaceuticals and healthcare. He has held leadership roles across AstraZeneca (Asia-Pacific), Wockhardt, Nicholas Piramal, ICI Pharmaceuticals, and Glaxo India. As Vice President at Abbott, he oversaw sales, manufacturing, and R&D for India’s largest healthcare MNC.
Currently an Operating Partner at Advent and Board Director for Quadria Capital, Mr. Iyer also serves as an Independent Director on the boards of RPG Life Sciences, Cohance Lifesciences, Themis Medicare, and Corona Remedies, contributing to strategic direction and value creation across the healthcare ecosystem.
Our diverse team is at the core of our success. We cultivate an inclusive, supportive workplace by:
Our Social Accountability Policy ensures respect for human rights and a thriving workplace.
Trust underpins our partnerships. We uphold ethical governance through:
Our Business Continuity and Information Security Policies ensure reliability and care in all operations.
We engage with communities to drive positive change through:
These efforts align with our mission to bring people and science together for a healthier world.
Sustainability is embedded in every stage of our operations. We integrate innovation and responsibility to deliver cutting-edge, sustainable solutions:
By prioritizing customer health, safety, and environmental responsibility, we create lasting value for our partners and the planet.
Cohance is committed to a sustainable future with ambitious goals:
At Cohance, ESG is our promise to go above and beyond, shaping a sustainable future for health science through passion, expertise, and unwavering responsibility.
Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet
Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet
Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet
Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet
Our great team of more than 1400 software experts.
We’ll help you test bold new ideas while sharing your.
Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet
Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet
Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet
Engitech is the partner of choice for many of the world’s leading enterprises, SMEs and technology challengers. We help businesses elevate their value through custom software development, product design,
Our great team of more than 1400 software experts.
We’ll help you test bold new ideas while sharing your.
Engitech is the partner of choice for many of the world’s leading enterprises, SMEs and technology challengers. We help businesses elevate their value through custom software development, product design,
Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.